An observational study in Gastro-Intestinal Disorder, sponsored by Methodist Health System. Recruiting at 1 site in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Methodist Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
The primary objective of this study is to provide a mechanism to store the following information about patients undergoing ERCPs at Methodist Dallas Medical Center. This registry will be permissive of quality improvement and research studies.
406 studies on the registry are indexed under Digestive System Diseases; 79 are open to participants now.
This study's planned enrollment of 100 is below the median of 400 across 105 observational studies indexed under Digestive System Diseases.
Browse Digestive System Diseases studies →Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who underwent ERCP and in MDI(Methodist Digestive Institute) registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients >15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025
Exclusion Criteria:
Patients \<15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.
Underwent ERCP between January 1, 2000 through December 31, 2025
Other: Patients undergoing ERCPs at Methodist Dallas Medical Center
The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.
Underwent ERCP
Patients undergoing ERCPs at Methodist Dallas Medical Center.
Time frame: 25 years
Plan to share: Yes — The investigator will make all possible efforts to ensure compliance with all policies regarding sharing of Protected Health Information or research information. Only de-identified Protected Health Information will be shared in relevant research mediums.
Supporting information: Study protocol
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.
Of 45 non-industry observational studies under Digestive System Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 12 months is below that.
Counting every sponsor, half of 56 studies reached it within 43 months; a quarter within 18 and three quarters within 102.
Digestive System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.